|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Frumento G, Rotondo R, Tonetti M, Damonte
G, Benatti U and Ferrara GB: Tryptophan-derived catabolites are
responsible for inhibition of T and natural killer cell
proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med.
196:459–468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Vita F, Orditura M, Galizia G, Romano
C, Lieto E, Iodice P, Tuccillo C and Catalano G: Serum
interleukin-10 is an independent prognostic factor in advanced
solid tumors. Oncol Rep. 7:357–361. 2000.PubMed/NCBI
|
|
4
|
Berghella AM, Pellegrini P, Del Beato T,
Adorno D and Casciani CU: IL-10 and sIL-2R serum levels as possible
peripheral blood prognostic markers in the passage from adenoma to
colorectal cancer. Cancer Biother Radiopharm. 12:265–272. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Orditura M, Romano C, De Vita F, Galizia
G, Lieto E, Infusino S, De Cataldis G and Catalano G: Behaviour of
interleukin-2 serum levels in advanced non-small-cell lung cancer
patients: Relationship with response to therapy and survival.
Cancer Immunol Immunother. 49:530–536. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kase H, Aoki Y and Tanaka K: Fas ligand
expression in cervical adenocarcinoma: Relevance to lymph node
metastasis and tumor progression. Gynecol Oncol. 90:70–74. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sheehan KM, O'Donovan DG, Fitzmaurice G,
O'Grady A, O'Donoghue DP, Sheahan K, Byrne MF, Conroy RM, Kay EW
and Murray FE: Prognostic relevance of Fas (APO-1/CD95) ligand in
human colorectal cancer. Eur J Gastroenterol Hepatol. 15:375–380.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gorter A and Meri S: Immune evasion of
tumor cells using membrane-bound complement regulatory proteins.
Immunol Today. 20:576–582. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Uyttenhove C, Pilotte L, Théate I,
Stroobant V, Colau D, Parmentier N, Boon T and Van den Eynde BJ:
Evidence for a tumoral immune resistance mechanism based on
tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med.
9:1269–1274. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Muller AJ, DuHadaway JB, Donover PS,
Sutanto-Ward E and Prendergast GC: Inhibition of indoleamine
2,3-dioxygenase, an immunoregulatory target of the cancer
suppression gene Bin1, potentiates cancer chemotherapy. Nat Med.
11:312–319. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Friberg M, Jennings R, Alsarraj M,
Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH and
Antonia SJ: Indoleamine 2,3-dioxygenase contributes to tumor cell
evasion of T cell-mediated rejection. Int J Cancer. 101:151–155.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Muller AJ and Prendergast GC: Marrying
immunotherapy with chemotherapy: Why say IDO? Cancer Res.
65:8065–8068. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Munn DH and Mellor AL: IDO and tolerance
to tumors. Trends Mol Med. 10:15–18. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mellor AL and Munn DH: IDO expression by
dendritic cells: Tolerance and tryptophan catabolism. Nat Rev
Immunol. 4:762–774. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Puccetti P: On watching the watchers: IDO
and type I/II IFN. Eur J Immunol. 37:876–879. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ball HJ, Sanchez-Perez A, Weiser S, Austin
CJ, Astelbauer F, Miu J, McQuillan JA, Stocker R, Jermiin LS and
Hunt NH: Characterization of an indoleamine 2,3-dioxygenase-like
protein found in humans and mice. Gene. 396:203–213. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Metz R, Duhadaway JB, Kamasani U,
Laury-Kleintop L, Muller AJ and Prendergast GC: Novel tryptophan
catabolic enzyme IDO2 is the preferred biochemical target of the
antitumor indoleamine 2,3-dioxygenase inhibitory compound
D-1-methyl-tryptophan. Cancer Res. 67:7082–7087. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qian F, Liao J, Villella J, Edwards R,
Kalinski P, Lele S, Shrikant P and Odunsi K: Effects of
1-methyltryptophan stereo-isomers on IDO2 enzyme activity and
IDO2-mediated arrest of human T cell proliferation. Cancer Immunol
Immunother. 61:2013–2020. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yuasa HJ, Takubo M, Takahashi A, Hasegawa
T, Noma H and Suzuki T: Evolution of vertebrate indoleamine
2,3-dioxygenases. J Mol Evol. 65:705–714. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun T, Chen XH, Tang ZD, Cai J, Wang XY,
Wang SC and Li ZL: Novel 1-alkyl-tryptophan derivatives
downregulate IDO1 and IDO2 mRNA expression induced by
interferon-gamma in dendritic cells. Mol Cell Biochem. 342:29–34.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Trabanelli S, Očadlíková D, Ciciarello M,
Salvestrini V, Lecciso M, Jandus C, Metz R, Evangelisti C,
Laury-Kleintop L, Romero P, et al: The SOCS3-independent expression
of IDO2 supports the homeostatic generation of T regulatory cells
by human dendritic cells. J Immunol. 192:1231–1240. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Metz R, Smith C, DuHadaway JB, Chandler P,
Baban B, Merlo LM, Pigott E, Keough MP, Rust S, Mellor AL, et al:
IDO2 is critical for IDO1-mediated T-cell regulation and exerts a
non-redundant function in inflammation. Int Immunol. 26:357–367.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
O'Neill DW, Adams S and Bhardwaj N:
Manipulating dendritic cell biology for the active immunotherapy of
cancer. Blood. 104:2235–2246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Iwashita Y, Goto S, Tominaga M, Sasaki A,
Ohmori N, Goto T, Sato S, Ohta M and Kitano S: Dendritic cell
immunotherapy with poly(D, L-2,4-diaminobutyric acid)-mediated
intratumoral delivery of the interleukin-12 gene suppresses tumor
growth significantly. Cancer Sci. 96:303–307. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nestle FO, Alijagic S, Gilliet M, Sun Y,
Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of
melanoma patients with peptide- or tumor lysate-pulsed dendritic
cells. Nat Med. 4:328–332. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Y, Zhang Y, Zheng X, Zhang X, Wang H,
Li Q, Yuan K, Zhou N, Yu Y, Song N, et al: Gene silencing of
indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis
through the suppression of NAD+ and inhibits in vivo tumor growth.
Oncotarget. 7:32329–32340. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng X, Koropatnick J, Li M, Zhang X,
Ling F, Ren X, Hao X, Sun H, Vladau C, Franek JA, et al:
Reinstalling antitumor immunity by inhibiting tumor-derived
immunosuppressive molecule IDO through RNA interference. J Immunol.
177:5639–5646. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yujuan Z, Na S, Jiamin F, Yanling L,
Xuelin Z, Shanshan P, Zhi Y, Xianfang Z, Yiguo C, et al: Synergic
therapy of melanoma using GNRs-MUA- PEI/siIDO2-FA through targeted
gene silencing and plasmonic photothermia. RSC. 6:79236–79237.
2016.
|
|
29
|
Zheng X, Koropatnick J, Chen D, Velenosi
T, Ling H, Zhang X, Jiang N, Navarro B, Ichim TE, et al: Silencing
IDO in dendritic cells: A novel approach to enhance cancer
immunotherapy in a murine breast cancer model. Int J Cancer.
132:967–977. 2013. View Article : Google Scholar
|
|
30
|
Zhang Y, Fu J, Shi Y, Peng S, Cai Y, Zhan
X, Song N, Liu Y, Wang Z, et al: A new cancer immunotherapy via
simultaneous DC mobilization and DC-targeted IDO gene silencing
using an immune-stimulatory nanosystem. Int J Cancer.
143:2039–2052. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng X, Vladau C, Zhang X, Suzuki M,
Ichim TE, Zhang ZX, Li M, Carrier E, Garcia B, Jevnikar AM, et al:
A novel in vivo siRNA delivery system specifically targeting
dendritic cells and silencing CD40 genes for immunomodulation.
Blood. 113:2646–2654. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
33
|
Banchereau J and Steinman RM: Dendritic
cells and the control of immunity. Nature. 392:245–252. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vacchelli E, Vitale I, Eggermont A,
Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L,
Kroemer G, et al: Trial watch: Dendritic cell-based interventions
for cancer therapy. OncoImmunology. 2:e257712013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Galluzzi L, Senovilla L, Vacchelli E,
Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E,
Zitvogel L and Kroemer G: Trial watch: Dendritic cell-based
interventions for cancer therapy. OncoImmunology. 1:1111–1134.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sørensen RB, Køllgaard T, Andersen RS, van
den Berg JH, Svane IM, Straten P and Andersen MH: Spontaneous
cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.
Cancer Res. 71:2038–2044. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Køllgaard T, Klausen TW, Idorn M,
Holmgaard RB, Straten PT and Andersen MH: Association of a
functional Indoleamine 2,3-dioxygenase 2 genotype with specific
immune responses. OncoImmunology. 1:441–447. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Merlo LMF, Pigott E, DuHadaway JB, Grabler
S, Metz R, Prendergast GC and Mandik-Nayak L: IDO2 is a critical
mediator of autoantibody production and inflammatory pathogenesis
in a mouse model of autoimmune arthritis. J Immunol. 192:2082–2090.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Baek S, Lee SJ, Kim MJ and Lee H:
Dendritic cell (DC) vaccine in mouse lung cancer minimal residual
model; Comparison of monocyte-derived DC vs. hematopoietic stem
cell derived-DC. Immune Netw. 12:pp. 269–276. 2012, View Article : Google Scholar
|
|
40
|
Hsu YL, Huang MS, Cheng DE, Hung JY, Yang
CJ, Chou SH and Kuo PL: Lung tumor-associated dendritic
cell-derived amphiregulin increased cancer progression. J Immunol.
187:1733–1744. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gardner A and Ruffell B: Dendritic cells
and cancer immunity. Trends Immunol. 37:855–865. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ghirelli C, Reyal F, Jeanmougin M,
Zollinger R, Sirven P, Michea P, Caux C, Bendriss-Vermare N,
Donnadieu MH, Caly M, et al: Breast cancer cell-derived GM-CSF
licenses regulatory Th2 induction by plasmacytoid predendritic
cells in aggressive disease subtypes. Cancer Res. 75:2775–2787.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xi HB, Wang GX, Fu B, Liu WP and Li Y:
Survivin and PSMA loaded dendritic cell vaccine for the treatment
of prostate cancer. Biol Pharm Bull. 38:827–835. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hossain DM, Dos Santos C, Zhang Q,
Kozlowska A, Liu H, Gao C, Moreira D, Swiderski P, Jozwiak A, Kline
J, et al: Leukemia cell-targeted STAT3 silencing and TLR9
triggering generate systemic antitumor immunity. Blood. 123:15–25.
2014. View Article : Google Scholar :
|
|
45
|
Fu C and Jiang A: Dendritic cells and CD8
T cell immunity in tumor microenvironment. Front Immunol.
9:30592018. View Article : Google Scholar
|
|
46
|
Koos D, Josephs SF, Alexandrescu DT, Chan
RC, Ramos F, Bogin V, Gammill V, Dasanu CA, De Necochea-Campion R,
Riordan NH, et al: Tumor vaccines in 2010: Need for integration.
Cell Immunol. 263:138–147. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lob S, Konigsrainer A, Schafer R,
Rammensee HG, Opelz G and Terness P: Levo- but not dextro-1-methyl
tryptophan abrogates the IDO activity of human dendritic cells.
Blood. 111:2152–2154. 2008. View Article : Google Scholar
|
